{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Clinical response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study.","groups":[{"description":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5.\n\nMaximum Tolerated Dose/Recommended Phase II Dose.","id":"OG000","title":"Phase II Dose Level 4 - Small Cell Lung Cancer (SCLC) Topotecan 1.25mg/m^2 IV/VX970 210mg/m^2 IV"},{"description":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5.\n\nMaximum Tolerated Dose/Recommended Phase II Dose.","id":"OG001","title":"Phase II DL 4 - Extrapulmonary Small Cell Cancer (EPSCC)Topotecan 1.25mg/m^2 IV/VX970 210mg/m^2 IV"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1/26 participants was not evaluable for response in the Phase II DL4 SCLC group. Phase II, DL4 Arm/Group is split into two groups for this outcome measure because the distinction is relevant for the phase II, DL4 since extrapulmonary small cell cancers (EPSCC) was an exploratory cohort of the phase II DL4 (added with an amendment).","reportingStatus":"POSTED","timeFrame":"Every two cycles (each cycle is 21 days) up to approximately 30 months.","title":"Ph II: Number of Participants With a Clinical Response","type":"PRIMARY","unitOfMeasure":"Participants"}